Infections in polymyositis and dermatomyositis: Analysis of 192 cases

Rheumatology

Volumn 49, Issue 12, 2010, Pages 2429-2437

  Chen, I Jung ^a   Tsai, Wen Pin ^b   Jan Wu, Yeong Jian ^a,b   Luo, Shue Fen ^a,b   Ho, Huei Huang ^a,b   Liou, Lieh Bang ^a,b   Chen, Ji Yih ^a,b   Kuo, Chang Fu ^b   Chang, Hsiao Chun ^b   Yang, Chung Han ^b   Yu, Kuang Hui ^a,b  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Dermatomyositis; Infection; Polymyositis; Risk factors; Survival

Indexed keywords

AZATHIOPRINE; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE;

ADULT; ARTHRALGIA; ARTHRITIS; ARTICLE; ASPIRATION PNEUMONIA; BACTEREMIA; BACTERIAL ARTHRITIS; BACTERIAL PNEUMONIA; CANDIDA ALBICANS; CANDIDIASIS; CLINICAL ASSESSMENT; COMORBIDITY; CYTOMEGALOVIRUS INFECTION; DERMATOMYOSITIS; ESCHERICHIA COLI; FEMALE; HERPES ZOSTER; HOSPITAL INFECTION; HUMAN; INCIDENCE; INFECTION RATE; INTERSTITIAL LUNG DISEASE; INTERVERTEBRAL DISK DEGENERATION; KLEBSIELLA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MENINGOENCEPHALITIS; MYCOBACTERIUM; MYCOBACTERIUM AVIUM; ONSET AGE; OPPORTUNISTIC INFECTION; OVERALL SURVIVAL; POLYMYOSITIS; PREDICTOR VARIABLE; PRIORITY JOURNAL; PULMONARY CRYPTOCOCCOSIS; SALMONELLA; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STEROID THERAPY; SURVIVAL RATE; TUBERCULOSIS; URINARY TRACT INFECTION;

ADULT; AGED; DERMATOMYOSITIS; FEMALE; HUMANS; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; POLYMYOSITIS; RETROSPECTIVE STUDIES; RISK FACTORS; STATISTICS AS TOPIC; SURVIVAL RATE; TAIWAN;

EID: 78549263747     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq279     Document Type: Article

References (59)

1. Medsger TA Jr, Robinson H, Masi AT. Factors affecting survivorship in polymyositis. A life-table study of 124 patients. Arthritis Rheum 1971;14:249-58.
2. Benbassat J, Gefel D, Larholt K et al. Prognostic factors in polymyositis/dermatomyositis. A computer-assisted analysis of ninety-two cases. Arthritis Rheum 1985;28:249-55.
3. Maugars YM, Berthelot JM, Abbas AA et al. Long-term prognosis of 69 patients with dermatomyositis or polymyositis. Clin Exp Rheumatol 1996;14:263-74.
4. Marie I, Hachulla E, Hatron PY et al. Polymyositis and dermatomyositis: short term and long term outcome, and predictive factors of prognosis. J Rheumatol 2001;28:2230-7.
5. Marie I, Hachulla E, Chérin P et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 2002;47:614-22.
6. Sultan SM, Ioannou Y, Moss K et al. Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology 2002;41:22-6.
7. Dankó K, Ponyi A, Constantin T et al. Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine 2004;83:35-42.
8. Airio A, Kautiainen H, Hakala M. Prognosis and mortality of polymyositis and dermatomyositis patients. Clin Rheumatol 2006;25:234-9.
9. Torres C, Belmonte R, Carmona L et al. Survival, mortality and causes of death in inflammatory myopathies. Autoimmunity 2006;39:205-15.
10. Chen IJ, Jan Wu YJ, Lin CW et al. Interstitial lung disease in polymyositis and dermatomyositis. Clin Rheumatol 2009;28:639-46.
11. Alarcón GS. Infections in systemic connective tissue diseases: systemic lupus erythematosus, scleroderma, and polymyositis/dermatomyositis. Infect Dis Clin North Am 2006;20:849-75.
12. Agustí C, Rañó A, Filella X et al. Pulmonary infiltrates in patients receiving long-term glucocorticoid treatment: etiology, prognostic factors, and associated inflammatory response. Chest 2003;123:488-98.
13. Marie I, Hachulla E, Chérin P et al. Opportunistic infections in polymyositis and dermatomyositis. Arthritis Rheum 2005;53:155-65.
14. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-7.
15. Chen YJ, Wu CY, Shen JL. Predicting factors of malignancy in dermatomyositis and polymyositis: a case-control study. Br J Dermatol 2001;144:825-31.
16. Ansell BM. Juvenile dermatomyositis. Rheum Dis Clin North Am 1991;17:931-42.
17. Euwer RL, Sontheimer RD. Amyopathic dermatomyositis: a review. J Invest Dermatol 1993;100:124S-7S.
18. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989;11:954-63.
19. Jeong SJ, Choi H, Lee HS et al. Incidence and risk factors of infection in a single cohort of 110 adults with systemic lupus erythematosus. Scand J Infect Dis 2009;41:268-74.
20. Lee PP, Lee TL, Ho MH et al. Recurrent major infections in juvenile-onset systemic lupus erythematosus-a close link with long-term disease damage. Rheumatology 2007;46: 1290-6.
21. Garner JS, Jarvis WR, Emori TG et al. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988;16: 128-40.
22. Cohen J, Pinching AJ, Rees AJ et al. Infection and immunosuppression. A study of the infective complications of 75 patients with immunologically-mediated disease. Q J Med 1982;51:1-15.
23. von Graevenitz A. The role of opportunistic bacteria in human disease. Annu Rev Microbiol 1977;31:447-71.
24. Wasko MC. Comorbid conditions in patients with rheumatic diseases: an update. Curr Opin Rheumatol 2004;16:109-13.
25. Kang I, Park SH. Infectious complications in SLE after immunosuppressive therapies. Curr Opin Rheumatol 2003;15:528-34.
26. Falagas ME, Manta KG, Betsi GI et al. Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review. Clin Rheumatol 2007;26: 663-70.
27. Ng KP, Ramos F, Sultan SM et al. Concomitant diseases in a cohort of patients with idiopathic myositis during long-term follow-up. Clin Rheumatol 2009;28:947-53.
28. Tani K, Tomioka R, Sato K et al. Comparison of clinical course of polymyositis and dermatomyositis: a follow-up study in Tokushima University Hospital. J Med Invest 2007;54:295-302.
29. Schwarz MI. The lung in polymyositis. Clin Chest Med 1998;19:701-12.
30. Viguier M, Fouéré S, de la Salmonière P et al. Peripheral blood lymphocyte subset counts in patients with dermatomyositis: clinical correlations and changes following therapy. Medicine 2003;82:82-6.
31. Hernández-Cruz B, Sifuentes-Osornio J, Ponce-de-León Rosales S et al. Mycobacterium tuberculosis infection in patients with systemic rheumatic diseases. A case-series. Clin Exp Rheumatol 1999;17:289-96.
32. Mukhopadhyay C, Garg A, Ayyagari A. First documented cure of a suggestive exogenous reinfection in polymyositis with same but multidrug resistant M. tuberculosis. BMC Infect Dis 2004;4:63.
33. Haq I, Isenberg DA. Myositis and swollen knees: disease or treatment complication? Ann Rheum Dis 2002;61: 544-6.
34. Ravn P, Munk ME, Andersen AB et al. Reactivation of tuberculosis during immunosuppressive treatment in a patient with a positive QuantiFERON-RD1 test. Scand J Infect Dis 2004;36:499-501.
35. Airio A, Kauppi M, Kautiainen H et al. High association of mycobacterial infections with polymyositis in a non-endemic country for tuberculosis. Ann Rheum Dis 2007;66:1404-5.
36. Nishi K, Myoh S, Bandoh T et al. An autopsy case of dermatomyositis associated with interstitial pneumonia probably due to cytomegalovirus infection. Nihon Kyobu Shikkan Gakkai Zasshi 1992;30:1975-80.
37. Yoda Y, Hanaoka R, Ide H et al. Clinical evaluation of patients with inflammatory connective tissue diseases complicated by cytomegalovirus antigenemia. Mod Rheumatol 2006;16:137-42.
38. Kaşifoǧlu T, Korkmaz C, Ozkan R. Cytomegalovirus-induced interstitial pneumonitis in a patient with dermatomyositis. Clin Rheumatol 2006;25: 731-3.
39. Takizawa Y, Inokuma S, Tanaka Y et al. Clinical characteristics of cytomegalovirus infection in rheumatic diseases: multicentre survey in a large patient population. Rheumatology 2008;47:1373-8.
40. Godeau B, Coutant-Perronne V, Le Thi Huong D et al. Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J Rheumatol 1994;21:246-51.
41. Kadoya A, Okada J, Iikuni Y et al. Risk factors for Pneumocystis carinii pneumonia in patients with polymyositis/dermatomyositis or systemic lupus erythematosus. J Rheumatol 1996;23:1186-8.
42. Bachelez H, Schremmer B, Cadranel J et al. Fulminant Pneumocystis carinii pneumonia in 4 patients with dermatomyositis. Arch Intern Med 1997;157:1501-3.
43. Henseler T. Mucocutaneous candidiasis in patients with skin diseases. Mycoses 1995;38(Suppl. 1):7-13.
44. Rhodus NL, Bloomquist C, Liljemark W et al. Prevalence, density, and manifestations of oral Candida albicans in patients with Sjögren's syndrome. J Otolaryngol 1997;26: 300-5.
45. Agustí C, Rañó A, Filella X et al. Pulmonary infiltrates in patients receiving long-term glucocorticoid treatment: etiology, prognostic factors, and associated inflammatory response. Chest 2003;123:488-98.
46. Fardet L, Rybojad M, Gain M et al. Incidence, risk factors, and severity of herpesvirus infections in a cohort of 121 patients with primary dermatomyositis and dermatomyositis associated with a malignant neoplasm. Arch Dermatol 2009;145:889-93.
47. Segal BH, Sneller MC. Infectious complications of immunosuppressive therapy in patients with rheumatic diseases. Rheum Dis Clin North Am 1997;23:219-37.
48. Lee P, Urowitz MB, Bookman AA et al. Systemic lupus erythematosus. A review of 110 cases with reference to nephritis, the nervous system, infections, aseptic necrosis and prognosis. Q J Med 1977;46:1-32.
49. Ginzler E, Diamond H, Kaplan D et al. Computer analysis of factors influencing frequency of infection in systemic lupus erythematosus. Arthritis Rheum 1978;21:37-44.
50. Brandt D, Gershwin ME. Common variable immune deficiency and autoimmunity. Autoimmun Rev 2006;5: 465-70.
51. Tha-In T, Bayry J, Metselaar HJ et al. Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol 2008;29:608-15.
52. Kaveri SV, Lacroix-Desmazes S, Bayry J. The antiinflammatory IgG. N Engl J Med 2008;359:307-9.
53. Jordan SC, Toyoda M, Vo AA. Intravenous immunoglobulin a natural regulator of immunity and inflammation. Transplantation 2009;88:1-6.
54. Rivero SJ, Díaz-Jouanen E, Alarcón-Segovia D. Lymphopenia in systemic lupus erythematosus. Clinical, diagnostic, and prognostic significance. Arthritis Rheum 1978;21:295-305.
55. Behan WM, Behan PO, Micklem HS et al. Abnormalities of lymphocyte subsets in polymyositis. Br Med J 1983;287: 181-2.
56. Iannone F, Cauli A, Yanni G et al. T-lymphocyte immunophenotyping in polymyositis and dermatomyositis. Br J Rheumatol 1996;35:839-45.
57. Miller FW, Love LA, Barbieri SA et al. Lymphocyte activation markers in idiopathic myositis: changes with disease activity and differences among clinical and autoantibody subgroups. Clin Exp Immunol 1990;81: 373-9.
58. Stone KB, Oddis CV, Fertig N et al. Anti-Jo-1 antibody levels correlated with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum 2007;56:3125-31.
59. Mielnik P, Wiesik-Szewczyk E, Olesinska M et al. Clinical features and prognosis of patients with idiopathic inflammatory myopathies and anti-Jo-1 antibodies. Autoimmunity 2006;39:243-7.